While treatment options for advanced NSCLC have expanded to include chemotherapy, targeted therapy, immunotherapy, radiation therapy, and combination therapies (47), significant challenges persist including severe side effects and limited efficacy, particularly in patients with KRAS mutations who frequently develop drug resistance (48, 49). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.